Cargando…
Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening
Inhibition of cytochrome P450 (CYP) is a major cause of herb–drug interactions. The CYP1A2 enzyme plays a major role in the metabolism of drugs in humans. Its broad substrate specificity, as well as its inhibition by a vast array of structurally diverse herbal active ingredients, has indicated the p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116189/ https://www.ncbi.nlm.nih.gov/pubmed/21686183 http://dx.doi.org/10.3390/ijms12053250 |
_version_ | 1782206233448546304 |
---|---|
author | Zhu, Ruixin Hu, Liwei Li, Haiyun Su, Juan Cao, Zhiwei Zhang, Weidong |
author_facet | Zhu, Ruixin Hu, Liwei Li, Haiyun Su, Juan Cao, Zhiwei Zhang, Weidong |
author_sort | Zhu, Ruixin |
collection | PubMed |
description | Inhibition of cytochrome P450 (CYP) is a major cause of herb–drug interactions. The CYP1A2 enzyme plays a major role in the metabolism of drugs in humans. Its broad substrate specificity, as well as its inhibition by a vast array of structurally diverse herbal active ingredients, has indicated the possibility of metabolic herb–drug interactions. Therefore nowadays searching inhibitors for CYP1A2 from herbal medicines are drawing much more attention by biological, chemical and pharmological scientists. In our work, a pharmacophore model as well as the docking technology is proposed to screen inhibitors from herbal ingredients data. Firstly different pharmaphore models were constructed and then validated and modified by 202 herbal ingredients. Secondly the best pharmaphore model was chosen to virtually screen the herbal data (a curated database of 989 herbal compounds). Then the hits (147 herbal compounds) were continued to be filtered by a docking process, and were tested in vitro successively. Finally, five of eighteen candidate compounds (272, 284, 300, 616 and 817) were found to have inhibition of CYP1A2 activity. The model developed in our study is efficient for in silico screening of large herbal databases in the identification of CYP1A2 inhibitors. It will play an important role to prevent the risk of herb–drug interactions at an early stage of the drug development process. |
format | Online Article Text |
id | pubmed-3116189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-31161892011-06-16 Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening Zhu, Ruixin Hu, Liwei Li, Haiyun Su, Juan Cao, Zhiwei Zhang, Weidong Int J Mol Sci Article Inhibition of cytochrome P450 (CYP) is a major cause of herb–drug interactions. The CYP1A2 enzyme plays a major role in the metabolism of drugs in humans. Its broad substrate specificity, as well as its inhibition by a vast array of structurally diverse herbal active ingredients, has indicated the possibility of metabolic herb–drug interactions. Therefore nowadays searching inhibitors for CYP1A2 from herbal medicines are drawing much more attention by biological, chemical and pharmological scientists. In our work, a pharmacophore model as well as the docking technology is proposed to screen inhibitors from herbal ingredients data. Firstly different pharmaphore models were constructed and then validated and modified by 202 herbal ingredients. Secondly the best pharmaphore model was chosen to virtually screen the herbal data (a curated database of 989 herbal compounds). Then the hits (147 herbal compounds) were continued to be filtered by a docking process, and were tested in vitro successively. Finally, five of eighteen candidate compounds (272, 284, 300, 616 and 817) were found to have inhibition of CYP1A2 activity. The model developed in our study is efficient for in silico screening of large herbal databases in the identification of CYP1A2 inhibitors. It will play an important role to prevent the risk of herb–drug interactions at an early stage of the drug development process. Molecular Diversity Preservation International (MDPI) 2011-05-18 /pmc/articles/PMC3116189/ /pubmed/21686183 http://dx.doi.org/10.3390/ijms12053250 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Zhu, Ruixin Hu, Liwei Li, Haiyun Su, Juan Cao, Zhiwei Zhang, Weidong Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title | Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title_full | Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title_fullStr | Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title_full_unstemmed | Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title_short | Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening |
title_sort | novel natural inhibitors of cyp1a2 identified by in silico and in vitro screening |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116189/ https://www.ncbi.nlm.nih.gov/pubmed/21686183 http://dx.doi.org/10.3390/ijms12053250 |
work_keys_str_mv | AT zhuruixin novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening AT huliwei novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening AT lihaiyun novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening AT sujuan novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening AT caozhiwei novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening AT zhangweidong novelnaturalinhibitorsofcyp1a2identifiedbyinsilicoandinvitroscreening |